SUMMARY The efficacy of pirmenol (a class I antiarrhythmic agent) as a converter of paroxysmal atrial fibrillation was investigated. Forty patients without congestive heart failure or a history of sinus node disorder were randomly allocated to receive either intravenous pirmenol (50-100 mg) or placebo in a double blind trial. 
SUMMARY The efficacy of pirmenol (a class I antiarrhythmic agent) as a converter of paroxysmal atrial fibrillation was investigated. Forty patients without congestive heart failure or a history of sinus node disorder were randomly allocated to receive either intravenous pirmenol (50-100 mg) or placebo in a double blind trial. In 12 of 20 patients sinus rhythm was restored [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] minutes after pirmenol, and in 3 of 20 patients in the control group it retumed within one hour. A nodal escape rhythm was seen during sinus slowing in one patient, but in other patients there was no sinus arrest, atrioventricular conduction disturbance, or hypotension. The ventricular rate was slightly increased in patients in whom sinus rhythm was not restored by pirmenol. The results indicate that pirmenol has an antifibrillatory effect on the atria. Sinus rhythm was restored rapidly after intravenous administration. It was well tolerated in patients with atrial fibrillation of recent onset.
Pirmenol has class I antiarrhythmic effects in Pur- kinje fibres.' It suppresses premature ventricular complexes in patients2 3 and terminates paroxysmal supraventricular tachycardia. 4 Depression of the fast inward current and a considerable increase in the duration of action potential in the rabbit atria have been reported,' which might suggest an antifibrillatory effect on the atria. Pirmenol converted atrial tachycardia and fibrillation to sinus rhythm in dogs.6
The present randomised double blind study was undertaken to examine the efficacy of intravenous pirmenol in the acute treatment of paroxysmal atrial fibrillation.
Patients and methods
Forty patients admitted to a hospital emergency department with atrial fibrillation of recent onset ( < 48 hours) participated in the study. Patients 3-8 (0-2) 4-1 (0 2) Heart disease* (n) 6 4 Previously documented atrial fibrillation (n) 8 6 History of high alcohol consumption (n) 5 1 Digitalis used (n) 3 2 Beta blockers used (n) [14] [15] [16] Duration of fibrillation10 and the size of the left atrium'
" influence the success of conversion. All the previously mentioned studies were largely performed in subjects with non-established paroxysmal or acute atrial fibrillation.9 16 Although the duration of fibrillation varied between studies, making comparison of the therapeutic effects difficult, fibrillation had not lasted more than one day in most patients. The success rate (60%) of pirmenol resembles that of procainamide disopyramide, and amiodarone for short term intravenous use. All of these agents restore sinus rhythm rapidly.
Pirmenol increases the effective refractory period of the atria in man (unpublished). Increased refractoriness could result either from depression of the fast response channel or from prolongation of the action potential, both of which effects have been observed in rabbit atria.5 A lengthening of the atrial effective refractory period theoretically reduces the number of disorganised activation wave fronts circulating in the fibrillating atria.18 Defibrillation may be the result of the increased probability of a conduction block with extinction of re-entry due to prolonged refractoriness. Furthermore, experiments in rabbits indicate that synchronisation of atrial activation wave fronts or reduction in their number may enhance the effective conduction of the atrioventricular node and reduce the degree of concealed conduction in the atrioventricular node and hence increase the transmission of impulses to the ventricles. 19 20 The anticholinergic effect of pirmenol2l probably also contributes to the increase in ventricular rate during atrial fibrillation.
A higher proportion of patients on beta blockers achieved sinus rhythm (7/8 vs 5/12; p=0-07), and there was no increase in heart rate in those patients who were on beta blockers. Whether beta blocking agents were causally related to the success of conversion by pirmenol cannot be definitely established.
It is unlikely that their use merely selected those (20) patients with a greater chance of conversion, because left atrial diameter or duration of fibrillation were no more favourable in those on beta blockers. Also, six of the eight patients had been on long term beta blockers treatment, and this indicates that these drugs were unable to prevent the paroxysm. Similar synergism between beta blockers and quinidine in atrial fibrillation has been suspected. 22 The dosages of pirmenol tested and plasma concentrations obtained paralleled those which are effective in other arrhythmias. Similar doses (50 mg) given intravenously once or twice terminated paroxysmal supraventricular tachycardia,4 and single short infusions of up to 150mg abolished premature ventricular complexes. 2 Rapid conversion of atrial fibrillation of recent onset by intravenous injection of a drug may avoid the need for electrical cardioversion and shorten hospital stay. A fall in blood pressure and depression of the sinus node and atrioventricular conduction system are potential adverse reactions of intravenous administration of drugs for conversion of atrial fibrillation.9'-14 Quinidine-like class I antiarrhythmics may also increase ventricular rate. " These untoward effects have prevented the use of intravenous conversion as a routine treatment. In the present study, from which patients with advanced cardiac diseases were excluded, restoration of sinus rhythm was uncomplicated except for a short period of nodal rhythm in one patient. Although the full electrophysiological effects of pirmenol are not known, by analogy with other fast inward current inhibitors23-25 it is likely to depress impulse formation and conduction when it is used to treat arrhythmias associated with sinus and atrioventricular nodal disorders. None of our patients had a hypotensive reaction. Pirmenol is known to increase blood pressure slightly and has only a slight myocardial depressant effect.26
In conclusion, pirmenol has an antifibrillatory effect in the atria. Its efficacy seems comparable to that of the agents presently available for rapid conversion of atrial fibrillation. It is well tolerated by patients without congestive heart failure or a diseased sinus node. 
